SALT LAKE CITY / Jul 22, 2025 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the third quarter of fiscal year 2025, following the close of regular trading on Thursday, August 7, 2025. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day.
This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company’s website and a replay of the call will be available from August 7th through August 21st at 877-660-6853 from anywhere in the U.S. or 201-612-7415 from non-U.S. locations. The replay conference call access code is 13754994. The listen-only webcast link is: https://event.choruscall.com/mediaframe/webcast.html?webcastid=t1AmHlX2
About Varex
Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit vareximaging.com.
| Last Trade: | US$11.97 |
| Daily Change: | 0.08 0.67 |
| Daily Volume: | 167,251 |
| Market Cap: | US$496.990M |
September 09, 2025 July 14, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load